Kesimpta (ofatumumab) for the Treatment of Relapsing Multiple Sclerosis (RMS)

Image 3-Kesimpta (ofatumumab)
Kesimpta can be self-administered subcutaneously via the Sensoready® autoinjector pen. Credit: Novartis Pharma AG.